Analyst Reco. Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
20.76 ^USD	+3.70%		-3.76%	-31.91%

04-15	Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	CI
03-25	Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	03-25	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	03-22	MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	03-22	DJ
Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $73 From $72, Maintains Buy Rating	02-23	MT
Wolfe Research Starts Intellia Therapeutics With Peer Perform Rating	02-15	MT
Morgan Stanley Adjusts Intellia Therapeutics' Price Target to $85 From $90, Keeps Overweight Rating	11-13	MT
Oppenheimer Slashes Price Target on Intellia Therapeutics to $70 From $80, Maintains Outperform Rating	11-13	MT
Goldman Sachs Adjusts Price Target on Intellia Therapeutics to $136 From $157, Maintains Buy Rating	11-10	MT
RBC Cuts Price Target on Intellia Therapeutics to $70 From $80, Keeps Outperform, Speculative Risk	11-10	MT
Wedbush Lowers Intellia Therapeutics' Price Target to $29 From $45, Maintains Neutral Rating	11-10	MT
Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $65 From $66, Maintains Buy Rating	23-08-07	MT
Barclays Adjusts Intellia Therapeutics Price Target to $90 From $148, Maintains Overweight Rating	23-08-04	MT
RBC Cuts Intellia Therapeutics' Price Target to $90 From $100, Keeps Outperform Speculative Risk Rating	23-07-07	MT
Chardan Trims Price Target on Intellia Therapeutics to $107 From $111, Maintains Buy Rating	23-06-13	MT
Citigroup Adjusts Price Target on Intellia Therapeutics to $44 From $39, Maintains Neutral Rating	23-05-08	MT
Morgan Stanley Adjusts Price Target on Intellia Therapeutics to $86 From $83, Maintains Overweight Rating	23-05-08	MT
Oppenheimer Adjusts Intellia Therapeutics Price Target to $90 From $93, Maintains Outperform Rating	23-05-08	MT
BMO Capital Adjusts Price Target on Intellia Therapeutics to $64 From $57, Maintains Outperform Rating	23-05-05	MT
Raymond James Adjusts Price Target on Intellia Therapeutics to $78 From $94, Maintains Outperform Rating	23-05-05	MT
Canaccord Genuity Starts Intellia Therapeutics at Buy With $66 Price Target	23-04-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Analyst Reco.

Filters